Laura Moschcovich, PhD
Dr. Laura Moschcovich joined OPKO Biologics (formerly Prolor Biotech) in 2007 as the Head of Downstream Development, leading the development of the purification process of MOD-4023 (CTP-growth hormone). In 2012 she became Project Manager responsible for overseeing three different projects in collaboration with different CMOs, taking the responsibility of the technology transfer of the processes developed at OPKO Biologics from development to production. Previously she led the CMC activities as Vice President, CMC Operationsof the Company and worked at Target-In Ltd., an Israeli startup company in a partnership with the Hebrew University of Jerusalem, as Head of Downstream Development where she was responsible for the development of the purification process of an innovative product. Dr. Moschcovich completed a post-doctoral fellowship and received her PhD in Biochemistry from Tel Aviv University.
Ahuva Bar-Ilan, PhD
VP Preclinical and Clinical Pharmacology
Ahuva Bar-Ilan joined OPKO Biologics (formely ModigeneTech and Prolor Biotech) in December 2006 as a senior scientist in the R&D department. Since 2012, she was an Associate Director at Prolor Biotech and was responsible for the development of immunogenicity and bio-analytical methods. Currently, she is a Director at OPKO’s pre-clinical department and is responsible for methods validation, toxicological and pharmacological activities. Prior to joining Modigentech, she was a senior scientist at NatSpears. Dr. Bar-Ilan completed her PhD in the Biochemistry and Microbiology department at Ben-Gurion University of the Negev, Israel.
Sagit Pinto-Finkel, CPA MBA
Sagit Pinto-Finkel joined OPKO Biologics in 2014. In 2015, she became the Director of Clinical Finance, and is responsible for all financial aspects of the clinical department.
Sagit has over 20 years of progressive experience in finance and business positions in pharma, high-tech and communications companies including multinational, private, and publically traded corporations.
Sagit is a CPA, holds a Bachelor’s Degree in Economics and Accounting from The Hebrew University, Jerusalem and an MBA, with a major in Finance (Cum Laude) from Tel Aviv University.
Director of CMC
Miri joined OBL in 2011 as a Research associate in downstream development department. In the following years, Miri held a variety of R&D positions including Associate Director of Downstream development and Senior Associate Director of Upstream Development. Prior joining OBL, Miri served as a Research assistant in an academic laboratory and Teaching assistant at the Department of Life Sciences at the Ben-Gurion University. Miri completed her M.Sc. and B.Sc. Magna (cum laude) in Life Sciences at Ben Gurion University.
Director Of QA
Dana had joined OPKO Biologics (formerly Prolor-Biotech) in the end of 2015 as Clinical QA in the Clinical department. She had functioned as the Operational team manager and Records Management team manager from 2017 to 2019, leading the Operational team of MOD-4023 (growth hormone CTP) in phase II and phase III global clinical trials and the Records Management team responsible for eTMF management of OPKO Biologics clinical trials. Since the end of 2019 Dana is leading the QA activities. Previously she worked as Quality Engineer in Omrix biopharmaceuticals, a Johnson & Johnson company. Dana holds a B.Sc. in Biotechnology Engineering from the Ben Gurion University of the Negev.
Gabi Faibish, LLB, MBA
Gabi Faibish joined OPKO Biologics in 2015. In 2020 he became the General Counsel, and is responsible for all legal, compliance and privacy matters. Gabi has extensive commercial and corporate experience, including international commercial law, privacy, intellectual property protection, labor law and other legal matters. Prior to joining OPKO, Gabi served in different positions in the defense industry. He holds an LLB from the College of Management; an MBA from the College of Management (with a major in Finance and IT); and a B.A. in Political Science from the Hebrew University of Jerusalem.